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Abstract
Several evidences showed that patients with gastrointestinal stromal tumors (GISTs) develop additional malignancies. However,
thorough incidence of second tumors remains uncertain as the possibility of a common molecular pathogenesis.
A retrospective series of 128 patients with histologically proven GIST treated at our institution was evaluated. Molecular analysis of
KIT and PDGFR-a genes was performed in all patients. Following the involvement of KRASmutation in many tumors’ pathogenesis,
analysis of KRAS was performed in patients with also second neoplasms.
Forty-six out of 128 GIST patients (35.9%) had a second neoplasm. Most second tumors (52%) raised from gastrointestinal tract
and 19.6% from genitourinary tract. Benign neoplasms were also included (21.7%). Molecular analysis was available for 29/46
patients with a second tumor: wild-type GISTs (n. 5), exon 11 (n. 16), exon 13 (n. 1), exon 9 (n. 1) KITmutations, exon 14 PDGFR-a
mutation (n. 2) and exon 18 PDGFR-amutation (n. 4). KIT exon 11mutations were more frequent between patients who developed a
second tumor (P=0.0003). Mutational analysis of KRAS showed a wild-type sequence in all cases. In metachronous cases, the
median time interval between GIST and second tumor was 21.5 months.
The high frequency of second tumors suggests that an unknown commonmolecular mechanismmight play a role, but it is not likely
that KRAS is involved in this common pathogenesis. The short interval between GIST diagnosis and the onset of second neoplasms
asks for a careful follow-up, particularly in the first 3 years after diagnosis.
Abbreviations: GIST= gastrointestinal stromal tumor, KIT = cKIT gene, KRAS= KRAS gene, PDGFRA= platelet-derived growth
factor receptor a, SDH = succinate dehydrogenase.
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1. Introduction peritoneum and rarely lymph nodes, bone, and lung. TheGastrointestinal stromal tumors (GISTs) are the most common
mesenchymal tumors of the digestive tract (about 15/106people/
year)[1]; GISTs occur anywhere along the gastrointestinal tract,
though they are most common in stomach (50–60%) and small
intestine (30–35%) and less frequent in colon, rectum, and
esophagus.[2] Common sites of metastases are liver andEditor: Chunxia Cao.
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malignant potential of a GIST is mainly determined by its size,
mitotic count, and the site of origin.[3] Disease-related symptoms
depend on tumor size and localization (e.g., gastrointestinal
bleeding, abdominal pain), but generally GISTs’ diagnosis occurs
incidentally either during abdominal surgery, at autopsy or
during other procedures for unrelated diseases.[4]
Over the last 2 decades, scientific interest about this tumor has
greatly increased as well as the knowledge of its complex biology.
Since the discovery of c-Kit gene (KIT) mutations in GISTs in
1998,[5] this neoplasm represent a paradigm of molecular target
therapies for solid tumors on the basis of the successful treatment
with imatinib, a tyrosine kinase inhibitor (TKI) able to inhibit the
growth of cells expressing KIT-mutant isoforms.[6] Although
most GISTs are sporadic and have no established risk factors, in
some cases they are observed in the context of hereditary
autosomical dominant syndromes due to germ-line KIT or
platelet-derived growth factor receptor a (PDGFRA) mutations
or other hereditary syndromes (Carney’s triad, Carney–Stratakis
syndrome, and Type 1 Neurofibromatosis).[7–9] The most
frequent driver mutations observed in GISTs involve KIT and
PDGFRA genes (85–90%); they lead to a constitutive activation
of KIT and/or PDGFRA receptors which, in turn, upregulate 2
main signal pathways (RAS-RAF-MEK-ERK and PI3K-AKT-
mTOR transducer protein kinases).[10] It is noteworthy that KIT
and PDGFRA genes are both located on chromosome 4q11-q12
Rodriquenz et al. Medicine (2016) 95:38 Medicineand might be evolved from a common ancestral gene through a
mechanism of duplication.[11] In addition, other genes whose
expression is relatively increased in GISTs compared to other soft
tissue tumors have been identified in several recent studies.
Particularly, 1 GIST-specific gene, encoding for the hypothetical
protein FLJ10261, named “Discovered On GIST 1” (DOG1)
was identified not only in typical GISTs but also inKIT-mutation-
negative GISTs.[12]
Recent evidences have demonstrated the complex biology of
GISTs and their heterogeneous nature, suggesting the need of
different diagnostic and therapeutic approaches. In 2013, Ricci
et al[13] proposed a schematic representation of GISTs based on
immunohistochemical and molecular profile, defined “GISTO-
GRAM.” Starting from the well-established evidence of immuno-
histochemical expression ofKIT (95%)[14] andDOG-1 (98%),[12]
as well as KIT (77%) and PDGFRA mutations (6.5%),[15] the
peculiarity of this work was to redefine the amount of GISTs
included in the designation “wild type.” Recently, mutually
exclusive mutations occurring in activating genes other than KIT
andPDGFRA have been found: 1.3%ofGISTs have amutation of
NF-1 gene [16] and 2% of GISTs harbor a mutation in the gene
encoding for succinate dehydrogenase (SDH), mainly occurring
in patients with Carney–Stratakis diad or Carney triad.[17]-
BRAFV600E and KRAS mutations were observed in 2% and 4%
of GISTs, respectively, with concurrent KIT or PDGFRA
mutations in a study conducted by Miranda et al[18] on 2 cohorts
coming from Italy and Ticino. In conclusion, the rate ofGISTs that
are reallywild type is below10%ofallGISTs, including those cases
in which a driver mutation has not yet been identified.
Emerging data suggest that the association of GISTs and
secondary neoplasms, either synchronous or not, is not
infrequent as several cases have been described, mostly as case
reports, but also in large case series and reviews.[19,20] The overall
frequency of second tumors in different series varied from 4.5%
to 43%, a value higher than expected in the general popula-
tion.[19] The most frequent GIST-associated cancers are gastro-
intestinal carcinomas, followed by extra-intestinal tumors
(lymphoma/leukemia, carcinomas of prostate, breast, kidney,
lung, female genital tract, carcinoid tumors, soft tissue and bone
sarcomas, malignant melanomas and seminomas). In spite of
these data, it has not yet been established whether the coexistence
of GIST with other tumors is stochastic or a result of related
pathogenetic mechanisms. Several hypotheses have been pro-
posed, including some cancerogenic agents which influence
neighboring tissues (e.g., N-methyl-N-nitro-N-nitrosoguanidine
—MNNG), Helicobacter pylori infection, and mutations of
proto-oncogenes encoding tyrosine kinases such as c-MET.[21–24]
However, available data are insufficient for supporting any
hypothesis, and no clinical study systematically analyzed the
molecular profile of GISTs associated with other malignancies.
The objectives of the present paper are to assess the prevalence
and histotype of second tumors in our GIST series, to compare
clinico-pathologic characteristics of patients affected by GIST
and other neoplasms to those affected by GIST only and, finally,
to evaluate gene mutations that could explain the coexistence of
GISTs and second tumors.2. Patients and methods
2.1. Patients, malignancies, and follow-up
A retrospective analysis was conducted on 128 patients with
histologically proven diagnosis of GIST treated in our Center2
between July 2002 and June 2014. We reviewed clinical records
in order to identify the cases with GISTs and associated tumors,
benign neoplasms included. Secondary tumors were defined as
synchronous if diagnosed during staging or surgery of GIST or
not-synchronous if previously or subsequently diagnosed. GIST
diagnosis was revised according to current diagnosis criteria.[25]
Immunohistochemical staining was performed with CD117,
CD34, desmin, and S100. Since 2010 also molecular analysis of
KIT (exon 9, 11 and 13) and PDGFRA (exon 12, 14 and 18)
genes was performed. Mutational analysis ofKRAS (exons 2 and
3) was also performed in the same cases for which KIT and
PDGFRAmutational status was available. The risk category was
defined assessing the tumor size and mitotic count following
Miettinen’s criteria.[26] Associated malignancies were classified
according to current World Health Organization (WHO)
classification of malignant neoplasms. Neurofibromatosis type
1 (NF-1) and familiar GIST were also included in this study. Age,
sex, tumor localization, morphological variant (epithelioid,
spindle-cell, and mixed), malignant potential (risk classification),
and selected immunohistochemical parameters were assessed.
The median follow-up of patients was 48.7 months (range:
2–141 months).
The study has been conducted in accordance with the rules
of the local Ethics Committee and the Declaration of Helsinki.
All patients provided a written consent for use of their
clinical data; a separate consent for molecular analyses was
obtained.2.2. Immunohistochemistry and PCR
The histological diagnosis of all GISTs has been confirmed at the
Department of Pathology of Università Cattolica del Sacro
Cuore. DNA was extracted from three 10mm-slides from
paraffin-embedded tissues using QIAamp DNAmini kit (Qiagen,
Milan, Italy), following the manufacturer’s protocol. KIT gene
(9, 11, 13, and 17 exons), PDGFRA gene (12, 14, and 18 exons),
and KRAS gene (2 and 3 exons) were amplified using the same
primers and polymerase chain reaction (PCR) conditions
previously described.[27,28] Briefly, DNA (100–200ng) was
amplified in a mixture containing 1PCR buffer (20mM Tris,
pH 8.3; 50 mMKCl; 1.5mM MgCl2), deoxyribonucleotide
triphosphates (200mM each), primers (20 pM each), and 0.5 U
GoTaq (Promega, Milan, Italy) in a final volume of 25mL. After
visualization onto agarose gel, stained with ethidium bromide
and visualized under UV light, PCR products were treated with
ExoSAP-IT (GE Healthcare, Milan, Italy) following the manu-
facturer’s protocol, amplified with the BigDye Terminator cycle-
sequencing kit (version 3.1; Applied Biosystems, Milan, Italy)
using forward and reverse primers, and sequenced with an ABI
PRISM 3100-Avant Genetic Analyzer (Applied Biosystems).
Water was used as a negative control. The sensitivity of this
method is 15% in our laboratory.2.3. Statistical analyses
Exact Fisher test and Chi-squared test were used to establish the
significance of the association between patients’ characteristics
and the coexistence of GIST and second tumors and the
relationship between GIST and associated tumors’ character-
istics. The differences in median age at diagnosis between all
patients affected by GIST and in patients with associated tumors
as well as the difference in median size of GIST at diagnosis
between these 2 groups were compared using Student’s t test. All
Table 1
Characteristics of all patients affected by GIST.
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Median age 65 (range: 23–86)
Median size 50 mm (range: 3–240)
Primary site
Gastro-oesophageal junction 1/128 (<1%)
Stomach 75/128 (59%)
Small intestine 37/128 (29%)
▪ Duodenum 13/37 (35%)
▪ Jejunum 17/37 (46%)





Syndromic GIST 2/128 (1.6%)
Multiple GISTs 3/128 (2.3%)




Lymph nodes 2/9 (22%)
Risk category




<5/50 HPF 68/128 (53%)
≥5/50 HPF 60/128 (47%)
Median HPF 4 (range: 0–100)
GIST = gastrointestinal stromal tumor.3. Results
We extracted clinical data of 128 patients with histologically
proven diagnosis of GIST treated in our Center. In total, 69 out of
128 patients were women; median age at diagnosis was 65 years
(range: 23–86 years). Median size of GIST at diagnosis was 50
mm (range: 3–240mm). The median mitotic rate was 4 (range:
1–100). The most common primary sites were: stomach (59%),
small intestine (29%), omentum (5%), and rectum (4%); anus,
gastro-oesophageal junction, and vagina were involved in <1%
of cases. Between small intestine GISTs, the most frequent
locations were jejunum (46%), duodenum (35%), and ileum
(22%). Twowomen affected by GISTs related toNF-1 syndrome
(1.7%) and 3 cases of multiple GISTs (2.5%) were also found.
Nine patients were metastatic at diagnosis (7.5%) and the
most frequent sites of metastases were liver (78%) and
peritoneum (56%); lymph node metastases were detected in
2 patients (22%), in association with other metastatic sites.
Thirty-twoGISTs (25%) belong to lowor very low-risk category,
38 to the intermediate category (30%) and 58 GISTs expressed a
high malignant potential (45%). Median follow-up time for all
GIST patients was 48.7 months (range: 2–141 months).
Characteristics of all patients affected by GIST are summarized
in Table 1.
In 46 out of 128 patients affected by GIST (36%), another
primary tumor was diagnosed; 37 were women (61%) but the sex
was not related to the presence of second malignancies (P=
0.2561); the median age at diagnosis was 68 years (range 44–80),
not statistically significant when patients with GIST and other
primary malignancies were compared to patients with isolated
GISTs (P=0.06). The median size of GISTs in patients with
second tumors was 50mm (range: 3–240cm), not significantly
different from the isolated GIST group (P=0.10). The median
mitotic rate was 2 (range: 1–100) and also in this case no
statistically significant difference was seen when the mitotic rate
of patients affected by GIST and another primary tumor was
compared to the mitotic rate of all 128 GISTs (P=0.48); high
mitotic rate (≥5/50 HPF) was not associated to second
malignancies even when we compared GIST plus associated
tumor group to all study population. Associated tumors most
frequently raised from gastrointestinal tract (52%; P=0.0001)
and genitourinary tract (19.6%), whereas only 4.3% of
associated tumors had an hepatobiliary origin. Thirty-six out
of 46 cases were malignant tumors (P=0.0002). The histotypes
of associated malignant tumors were the following: gastric
adenocarcinoma (n=6), gastric diffuse large B cell lymphoma
(n=1), colorectal adenocarcinoma (n=6), esophageal squamous
carcinoma (n=2), duodenal neuroendocrine tumor (n=1),
adenocarcinoma of the papilla of Vater (n=2), hepatocellular
carcinoma (n=1), biliary duct carcinoma (n=1), pancreatic
adenocarcinoma (n=1), pancreatic neuroendocrine tumor (n=
1), lung adenocarcinoma (n=3), breast ductal carcinoma (n=2),
endometrial sarcoma (n=1), endometrial adenocarcinoma (n=
1), prostatic adenocarcinoma (n=2), urothelial carcinoma of the
bladder (n=1), thyroid papillary carcinoma (n=1), peritoneal
mesothelioma (n=1), retroperitoneal liposarcoma (n=1), Hodg-
kin’s Lymphoma (n=1). The benign neoplasms included in our
series were: gastrointestinal multiple fibrous inflammatory polyps
(n=2), gastric tubular adenoma (n=2), colic adenoma (n=1),
pancreatic intrapapillar mucinous neoplasm (n=1), meningioma3
(n=1), ovarian cystadenoma (n=1), uterine leiomyoma (n=1),
mucinous cystadenoma of appendix (n=1).
Diagnosis of associated malignancies was performed prior to
GIST diagnosis in 20% of patients, after GIST diagnosis in 17%
and it was synchronous in 63% of cases. In metachronous cases,
the median time interval between GIST and second tumor
diagnosis was 21.5months. Sixteen out of 29 patients (55%)with
synchronous diagnosis of GISTs and other primary tumors had
symptoms related to GIST (abdominal pain, bleeding); thus,
secondmalignancy was detected only at the time of GISTworkup
or resection. In the remaining 13 cases, GIST was an incidental
finding during pre-operatory CT scan or abdominal surgery for
the associated primary tumor, and in most cases, it was a micro-
GISTs (<1cm).
Characteristics of patients affected by GIST and other primary
tumors are summarized in Table 2.
A third tumor was diagnosed during the follow-up period in 4
out of 46 patients (8.7%). In 1 case, 7 years after the diagnosis of
breast cancer, a gastric GIST was surgically resected and 19
months later also a gastric adenocarcinoma was found. A second
patient developed a multifocal hepatocellular carcinoma 2 years
after diagnosis of gastric GIST, synchronous to an esophageal
adenocarcinoma. The third patient was affected either by
synchronous gastric GIST, gastric leiomyoma, and duodenal
NET. The last one developed synchronous prostatic adenocarci-
noma and bladder cancer and 10 years later a jejuneal GIST.
Overall 13 out of 46 patients received adjuvant Imatinib.
During the follow up period, none of these patients developed
Table 2




Male 19/46 (39%) 0.2561
Female 27/46 (61%)
Median age at diagnosis 68 (range: 40–81) –
Median size 37 mm (range: 3–240) –
Mitotic rate
<5/50 HPF 27/46 (59%)
≥5/50 HPF 19/46 (41%) 0.2561
Median 2 (range: 0–100)
Primary site of associated tumors <0.0001







Liver and biliary ducts 2/46 (4.3%)
Liver 1/46 (2.1%)
Biliary ducts 1/46 (2.1%)












Hematological neoplasms 1/46 (2.1%)
Malignant tumors 36/46 (78.3%) = 0.0002
Timing of diagnosis
Synchronous 29/46 (63%)
Prior to GIST diagnosis 9/46 (20%) <0.0001
After GIST diagnosis 8/46 (17%)
GIST = gastrointestinal stromal tumor.
Rodriquenz et al. Medicine (2016) 95:38 Medicinemetastases from GIST, whereas 4 patients with a synchronous
tumor died because of the other malignancy (colangiocarcinoma,
HCC, pancreatic adenocarcinoma, gastric adenocarcinoma). No
patient died because of GIST.
Twenty-nine out of 46 patients with GIST and associated
malignancies were evaluated for mutational analysis of KIT
(exons 9, 11, 13) and PDGFRA (exons 12, 14, 18). Five GISTs
were wild type, whereas 14 patients had a mutation in the KIT
gene (12 in exon 11, 1 in exon 9 and 1 in exon 13) and 4 patients
had mutation in the PDGFRA gene, 2 in exon 14 and other 2 in
exon 18 (D842V). In those patients harboring a mutation in exon
11 of KIT gene, 8 had heterozygous mutations, 2 patients had a
deletion, and in 2 cases was found a complex mutation.
Interestingly, KIT mutations seems to be related to the presence
of other primary tumors (P=0.0003) and specifically exon 11
mutations (P<0.0001). Both cases of PDFGRA mutation in
exon 14 were germline mutations and were associated with
fibrous gastrointestinal polyps; in addition, in 1 case, it was
associated with exon 11 deletion of KIT. Mutational analysis of
KRAS (exons 2 and 3) was performed in all 29 cases evaluated for4
KIT and PDGFRA mutation and in all patients it resulted wild
type (Table 3). No relationship between genetic mutations and
risk categories of GISTs was found (P=0.26).4. Discussion
Over the past decade, several evidences have demonstrated the
heterogeneous genetic pattern of GIST; most GISTs are driven by
a pathological activation of KIT or PDGFRA, however, other
genetic changes—including gain of function BRAF mutations[29]
and loss of succinate dehydrogenase (SDH) complex activi-
ty[30]—have been identified in the subset of wild-type GISTs.
Recently, KRAS codon 12 and 13 mutations were reported in a
small subset of KIT or PDGFRA mutant GISTs.[18] No specific
genetic alterations have been identified in sporadic GISTs
associated to secondary malignancies as opposed to syndromic
GISTs (e.g., NF-1 and triad of Carney–Stratakis) in which
peculiar gene mutations were found driving pathogenesis both of
GISTs and other related tumors.[16,17]
Recent studies have shown a high frequency of second
malignancies in GIST patients, ranging from 2.95 to 43% in
different series.[21,31–34] This discrepancy could be explained by
selection criteria used in each study, in particular, regarding the
inclusion of benign neoplasms. In the present study, other tumors
were associated to GIST in 46 out of 120 patients (38.3%); this is
one of the largest monoinstitutional series on this topic and the
high level of association might be explained by inclusion of
benign neoplasms and long period of observation and follow-up.
Themost frequent neoplasms associated with concomitant GISTs
are located in gastrointestinal tract with gastric and colorectal
adenocarcinomas being leading types according to literature.[20]
To our knowledge, no cases of GISTs coexisting with pancreatic
IPMN and peritoneal mesothelioma have been previously
reported. In our series, GISTs diagnosed synchronously to
second malignancy were more frequently symptomatic than
reported in literature (16/29; 55%); thus, the associated tumor
wasmostly diagnosed incidentally. On the other hand, 13 cases in
this group (45%) were incidental findings during abdominal
surgery for the second tumor and classified as microGISTs (<1
cm). This result differs frommost of the studies available in which
almost all cases of synchronous GISTs were microGISTs or
asymptomatic GISTs detected incidentally during surgery. Three
possible reasons could be proposed for this event: (1) very
thorough abdominal cavity inspection was performed during
surgery or on examination of resection specimen to detect other
lesions, even of small size; (2) more attention was paid to GIST-
related symptoms which could be overlooked during diagnostic
investigations for other malignancies (3) some microGISTs may
not have been addressed by the surgeon to oncologist attention if
also second cancer belonged to early stage and did not require
any additional treatment, so that cases are not included in the
database.
The follow-up period ranged from 2 to 141 months with a
median of 48.7 months. In 8 patients (17%), second tumor was
detected after diagnosis of GIST; the median time interval
between GIST and second tumor was 22.8 months. Second
malignancies of this subgroup not only raised from gastrointesti-
nal tract (2 gastric adenocarcinoma, 1 gastric diffuse large B cell
lymphoma and 1 colic adenocarcinoma), but also involved lung
(2 cases), breast and prostate (1 case). Two cases of gastric
adenocarcinoma growth in the same organ of previous high risk
GIST both within 18 months from GIST diagnosis. This result
suggests a possible common etiologic agent acting on neighbor
Table 3
GIST mutations and associated malignancies.
GIST mutation N° of cases Associated malignancy P
Wild type 5/29 (17.2%) Adenocarcinoma of ampolla of Vater (S) =0.0003
Colic adenocarcinoma (S)




• Exon 9 1/18 (5.6%) Pancreatic adenocarcinoma (S)
• Exon 11 16/18 (88.9%)
▪ Heterozygous mutations 8/16 (50%) Rectal adenocarcinoma (S)
Endometrial sarcoma (S)






▪ Complex mutations 3/16 (18.7%) Gastric adenocarcinoma (S)
Biliary duct carcinoma (S)
▪ Deletions 5/16 (31.3%) Esophageal squamous carcinoma (S)
Meningioma (NS)
Uterine leiomioma (S)
Adenocarcinoma of ampolla of Vater (S)
Gastric adenocarcinoma (S)
• Exon 13 1/18 (5.6%) Gastric adenocarcinoma (M)
PDGFRA 6/29 (20.7%)
• Exon 14 2/6 (33%) Inflammatory fibrous polips (S)
• Exon 18 (D842V) 4/6 (67%) Peritoneal mesothelioma (S)
Hepatocellular carcinoma (NS)
Mucinous cystadenoma of appendix (S)
Gastric tubular adenoma (S)
GIST = gastrointestinal stromal tumor, S= synchronous tumor, NS=nonsynchronous tumor.
Rodriquenz et al. Medicine (2016) 95:38 www.md-journal.comtissues and should lead us to perform gastroscopy more
frequently than annually. Ultimately, the relative short interval
between GIST diagnosis and the onset of second neoplasms
suggests the need to perform strict follow-up particularly in the
first year after diagnosis; screening exams for breast and prostate
cancer should not be overlooked in these cases. Only 1 patient in
cohort of GISTs associated with second malignancies was
metastatic and no one died for GIST, whereas 4 patients died
for related tumors (colangiocarcinoma, HCC, pancreatic adeno-
carcinoma, gastric adenocarcinoma), that negatively affected the
prognosis.
The occurrence of both metachronous and concomitant GISTs
with other neoplasms has raised the question of whether such an
event is a stochastic one or expression of a causal relationship.
Several hypotheses have been proposed, but the question is still
matter of debate: a possible explanation could be the existence of
a unique genetic mutation involving different cells and leading to
2 different neoplasms. In our study, KIT exon 11 mutations were
more frequent between patients who developed a second tumor
(P=0.0003), but the sample is too small to have a clinical
relevance; in addition, exon 11 mutations are the most frequent
genetic alterations in GISTs, so a definitive conclusion cannot be
drawn. Only fibrous gastrointestinal polyps seem closely related
to germline mutations of PDGFRA exon 14, as reported in
previous studies.[35]
KRAS and the other members of RAS family (HRAS, NRAS)
encode for important proteins which release mitogenic growth
signals into cytoplasm and nucleus. Gain-of-function mutations5
of RAS caused alterations of RAS-RAF-MAPK signaling
pathway leading to increased cell proliferation, that plays an
important role in the pathogenesis of a wide variety of human
malignancies, including colon-rectum, pancreas, lung, breast
cancer, and, rarely, sarcomas. In 2012,Miranda et al[18] reported
3 cases of concurrent KRAS mutations in KIT or PDGFRA
mutant GIST in 2 cohorts of patients tested independently in Italy
and Ticino.[18] None of the patients carrying concomitant
mutations of KIT and KRAS gene was treated with imatinib;
these patients underwent surgical eradication of the tumor and
were classified as disease-free subjects at the last follow-up. For
this reason, the authors explored the biologic consequences of the
concomitant presence of KIT and KRAS mutations through in
vitro experiments and found that KRAS mutations can cause
resistance of KIT-mutant GISTs to imatinib; in fact, imatinib was
able to switch off the mutated receptor KIT but not the
downstream signaling triggered by RAS-RAF effectors. More
recently, Lasota et al[36] performed KRAS mutational analysis in
a larger cohort of GISTs (514 cases) without finding any case of
KRAS mutations. However, none of the 2 above-cited studies
evaluated GISTs coexisting with other malignancies. Considering
the role of RAS-RAF-MAPK signaling pathway as effector of
activation of KIT and PDGFRA tyrosine kinases and the
implication of RAS mutations in cancerogenesis of several
tumors, some KRAS gene aberration might be shared by GISTs
and associated tumors. In our study, we did not find anymutation
in KRAS among cases for which KIT and PDGFRA mutational
status was available, suggesting that probably KRAS mutations
[14] Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, et al. CD117: a
Rodriquenz et al. Medicine (2016) 95:38 Medicinedo not play a key-role in cancerogenesis of GISTs and associated
malignancies.
On the other hand, it has been suggested that patients affected
by GIST with a second primary neoplasm—either synchronous
or metachronous—had GISTs with increased mitotic rate (≥5 per
50 high-power fields) (P=0.0006).[37] In our series, no difference
in the median mitotic rate was seen between GIST associated to
second neoplasms and all study population (P=0.49) and high
mitotic rate (≥5/50 HPF) seems not related too.5. Conclusions
This is one of the largest series on second tumors and GISTs as
monoinstitutional experience. As previously considered,[38] the
high frequency of second tumors, synchronous or metachronous,
in patients affected by GISTs suggests that GIST could be
considered as a “sentinel tumor.” Thus, after diagnosis of GIST,
the risk of a second concomitant neoplasm, especially in
gastrointestinal tract, should be considered and a careful surgical
and pathological inspection is suggested. Surveillance not only
for GIST but also for second malignancies is an important
component of the management of patients affected by GIST,
particularly in the first years after diagnosis. In addition,
esophagogastroduodenoscopy should be planned more frequent-
ly than annually and screening for breast and prostate cancer
should also be considered. KIT, PDGFRA, and KRAS
mutational status does not seem to play a key-role in a common
pathogenesis of GIST and second malignancies, but no definitive
conclusions can be drawn due to the lack of molecular analysis in
second tumors of our sample. Thus, more studies are required
to investigate the genetic mechanism of cancerogenesis and
progression associating GIST and coexisting tumors.References
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